When the FDA Cancels a Meeting and a Biotech Disappears
In October 2025, Kezar Life Sciences had a crucial meeting with the FDA scheduled that was essentially its lifeline. This wasn't a routine meeting or a bureaucratic formality; it was the regulatory milestone on which the entire funding structure of the company depended. Investors knew it. The team knew it. CEO Chris Kirk, with over two decades in biotechnology, knew it better than anyone.
The FDA canceled that meeting without any explanation.
Four months later, in February 2026, the agency finally agreed to reschedule it and approved the design of the clinical trial. By then, Kezar had already laid off most of its 60 employees, auctioned off laboratory equipment, and sold office furniture. The only items they kept were the table and chairs from a conference room, just in case they needed to sit down with regulators again. In April 2026, the company was acquired by Aurinia Pharmaceuticals, although timelines for advancing the autoimmune hepatitis drug remain uncertain.
This situation is mostly being interpreted as a story about the unpredictability of the FDA. However, I read it differently: it is an autopsy of a business model built on a single-node trust network.
The Illusion of Resilience in Serial Funding Models
Small biotech companies operate under a cascading funding logic: one round of capital leads to the next, and each transition depends on demonstrating regulatory progress to investors. There’s no room for error. No cushion of operating income. The model works as long as the flow of positive signals is continuous. When one signal fails, the entire chain collapses.
Kezar did not have a diversified network of institutional validation. It had one critical contact point: the FDA. When that point vanished for four months, investors didn’t wait. Trust, which in biotech is valued like capital, evaporated before cash ran out.
Kirk described the FDA’s recent behavior as "stochastic and perhaps even capricious." This description, coming from someone with his background, isn't mere emotional venting; it’s an engineering diagnosis. A system that was predictable, though not always favorable, became random. And business models designed to tolerate predictable friction do not withstand randomness.
What no one is discussing deeply enough is that this vulnerability is not just financial. It’s structural. It relates to how trust networks are built, or more often how they aren’t built, within the sector.
The Social Capital Kezar Didn’t Have Time to Build
Companies that survive regulatory shocks do so not because they have more money, though that helps. They survive because they have denser networks: alliances with large pharmaceutical companies that absorb the risks of waiting, relationships with multiple regulatory agencies in different jurisdictions, academic collaboration agreements that keep scientific programs alive regardless of approval status.
Moderna and BioNTech are examples frequently cited in industry reports. They don’t survive regulatory turbulence because they are smarter; they survive it because they built, years in advance, a network of interlocutors that distributes risk across multiple vectors. They have teams dedicated to early interactions with regulators, adaptive trials that allow for design modifications without restarting the process, and manufacturing structures aligned with review criteria before the review even begins.
All this costs money that a company with 60 people developing a treatment for a rare disease can hardly afford. Here lies the real trap of the model: small biotechs focused on orphan diseases are precisely the ones that need a robust network of institutional relationships the most and have the least resources to build one. The result is a concentration of risk such that a four-month meeting cancellation is enough to destroy years of scientific work.
The case of IO Biotech, which filed for bankruptcy on March 31, 2026, after its cancer vaccine was rejected, follows the same logic. Lipella Pharmaceuticals on the same day. f5 Therapeutics at the beginning of 2026. Nido Biosciences after a Phase 2 failure. We are not witnessing a series of individual tragedies. We are seeing a pattern that reveals the systemic fragility of a business model where scientific knowledge and social capital operate in completely separate silos.
Homogeneity at the Decision-Making Table and Blind Spots Costing Lives
There’s another dimension in this case that conventional financial analyses fail to capture, which is the composition of the boards of these small biotech companies.
When a board is predominantly composed of individuals with similar backgrounds—mostly scientists or financiers experienced in the same types of companies and with connections to the same institutional actors—the result is a risk strategy that shares the same blind spots. Everyone assumes that the FDA will remain predictable because they have all lived through decades when that was true. Everyone builds the financial model on the same premise of regulatory continuity. No one at the table has the profile or mandate to ask what happens if the central trust node fails.
That question isn’t philosophical. It has an operational price tag: how many weeks of runway do we maintain if the next regulatory milestone is delayed six months? Do we have an active second regulatory jurisdiction, such as the European Medicines Agency, where we can demonstrate progress while the FDA resolves its internal situation? Do we have a pre-existing relationship with a larger company that could absorb the program if capital runs out?
The companies that do survive have those conversations because they have, somewhere in their governance structure, voices that do not share the underlying optimism of those who built the scientific program from scratch. Diversity at the board level is not a concession to corporate politics. It is the mechanism by which an organization asks itself questions that its founding core is structurally incapable of asking.
Aurinia Pharmaceuticals acquired Kezar when the damage was already done. The drug may proceed, or it may not, depending on the integration assessment conducted by the buyer. The 60 employees are out of work. Patients with autoimmune hepatitis—a serious disease with limited therapeutic options—are still waiting.
A $6.3 Billion Fund Doesn't Change the Equation for Those on the Ground
In the same week that the Kezar case gained public visibility, an investment firm announced the closing of a $6.3 billion vehicle, the largest in its history, aimed at financing Phase III trials in partnership with pharmaceutical, medical technology, and biotech companies. That figure is revealing for what it indicates about where sector capital is moving.
Institutional money is migrating to later stages where regulatory risk is already partially absorbed and return profiles are more predictable. This leaves a growing void in early and mid-stage developments, precisely where companies like Kezar operate. It’s not that capital has disappeared from the sector. It is being concentrated among players that have already crossed the risk threshold that killed these companies.
For corporate leadership in biotechnology, especially in small and medium-sized enterprises focused on rare diseases, the operational lesson is direct: resilience cannot be bought with the next funding round. It must be built before it is needed, by distributing risk across multiple institutional relationships, multiple regulatory jurisdictions, and governance structures that include voices capable of challenging the assumptions that the founding team takes for granted.
Take a look at your board's composition in the next session. If everyone reached the same type of conclusions throughout their careers, if they all built their networks in the same circles, and they all share the same mental model of how the relationship with regulators works, then you don’t have a board—you have a mirror. And mirrors do not warn about what is coming from the sides.
